Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E84.53 EPS (ttm)1.99 Insider Own0.90% Shs Outstand197.81M Perf Week-1.80%
Market Cap33.28B Forward P/E29.08 EPS next Y5.78 Insider Trans-3.52% Shs Float196.46M Perf Month0.44%
Income400.60M PEG2.71 EPS next Q1.15 Inst Own97.10% Short Float2.01% Perf Quarter3.65%
Sales1.92B P/S17.32 EPS this Y-0.80% Inst Trans-0.61% Short Ratio3.34 Perf Half Y-8.35%
Book/sh14.56 P/B11.55 EPS next Y15.52% ROA12.10% Target Price197.05 Perf Year57.55%
Cash/sh8.06 P/C20.87 EPS next 5Y31.16% ROE15.50% 52W Range100.89 - 185.43 Perf YTD26.60%
Dividend- P/FCF94.59 EPS past 5Y44.70% ROI10.20% 52W High-9.28% Beta0.65
Dividend %- Quick Ratio5.30 Sales past 5Y43.00% Gross Margin91.30% 52W Low66.74% ATR4.40
Employees1774 Current Ratio5.60 Sales Q/Q38.50% Oper. Margin39.10% RSI (14)57.06 Volatility2.08% 2.58%
OptionableYes Debt/Eq0.03 EPS Q/Q72.90% Profit Margin20.90% Rel Volume0.62 Prev Close166.47
ShortableYes LT Debt/Eq0.01 EarningsJul 24 BMO Payout0.00% Avg Volume1.18M Price168.22
Recom1.90 SMA203.00% SMA503.45% SMA20010.30% Volume734,288 Change1.05%
25-Apr-14Reiterated Stifel Buy $219 → $220
11-Mar-14Reiterated UBS Buy $185 → $202
11-Mar-14Reiterated Stifel Buy $207 → $219
06-Mar-14Reiterated Barclays Overweight $181 → $193
10-Feb-14Reiterated Deutsche Bank Buy $125 → $205
31-Jan-14Reiterated Stifel Buy $138 → $207
31-Jan-14Reiterated Canaccord Genuity Buy $161 → $200
31-Jan-14Reiterated Barclays Overweight $141 → $181
30-Jan-14Reiterated Brean Capital Buy $142 → $200
10-Jan-14Reiterated Barclays Overweight $127 → $141
06-Jan-14Reiterated UBS Buy $130 → $150
06-Jan-14Reiterated Canaccord Genuity Buy $138 → $161
25-Oct-13Reiterated Stifel Buy $131 → $138
25-Oct-13Reiterated Barclays Overweight $121 → $127
26-Jul-13Reiterated Barclays Overweight $118 → $121
26-Apr-13Reiterated UBS Buy $120 → $123
24-Sep-12Reiterated Canaccord Genuity Buy $115 → $132
25-Apr-12Reiterated Canaccord Genuity Buy $95 → $100
25-Apr-12Reiterated Barclays Overweight $84 → $104
26-Mar-12Initiated Canaccord Genuity Buy $95
20-Aug-14 10:08AM  Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus Zacks
19-Aug-14 04:25PM  Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 Zacks
18-Aug-14 01:46PM  Jazz, Celgene Lead Top 4 Drugmaker Profit Margins at Investor's Business Daily
14-Aug-14 04:02PM  Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Gurufocus
03:10PM  [video] Red hot biotech stocks at CNBC
13-Aug-14 04:57PM  Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting Business Wire
08-Aug-14 04:45PM  GW Pharma, Insys Face Off In Cannabis Drug Space at Investor's Business Daily
01:03PM  Today's Stocks Driving Success For The Health Care Sector at TheStreet
10:28AM  Wall Street Transcript Interview with Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC) Wall Street Transcript
10:00AM  VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales Zacks
07-Aug-14 06:02PM  Double-Bottom Bases Demand A Tenacious Attention Span Investor's Business Daily
11:40AM  NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Zacks
05-Aug-14 01:00PM  Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook Zacks
04-Aug-14 10:10AM  Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss Zacks
08:37AM  Politicians Shouldn't Question Drug Costs But Rather Their Value. Lessons From Soliris And Sovaldi. at Forbes
01-Aug-14 06:30AM  European Commission Grants Orphan Drug Designation to SolirisĀ® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) Business Wire
31-Jul-14 02:51PM  Many Leading Stocks Damaged As Market Tumbles Broadly at Investor's Business Daily
01:04PM  ALEXION PHARMACEUTICALS INC Financials EDGAR Online Financials
30-Jul-14 05:18PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
28-Jul-14 06:03PM  Biotech ETF Price Swings May Signal Need For Caution at Investor's Business Daily
01:40PM  Midday movers: Cummins, Dollar Tree, Zillow & More at CNBC
25-Jul-14 12:19PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
24-Jul-14 05:18PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
05:07PM  Celgene, Alexion Beat Estimates, But Biotechs Fall at Investor's Business Daily
03:15PM  Stock market live blog: Sodastream pops, while Angie's List dives; S&P 500 tries for record at MarketWatch
02:45PM  Alexion Pharmaceuticals Q2 Earnings In Line; Revises View Zacks
11:44AM  Biotechs beat estimates, but the Street wants more at MarketWatch
11:39AM  Video: Celgene, Alexion Earnings Top, But Stocks Fall at Investor's Business Daily
11:39AM  Video: Celgene, Alexion Earnings Top Street, But Stocks Fall at Investor's Business Daily
11:39AM  Celgene, Alexion Earnings Top Street, But Stocks Fall at Investor's Business Daily
10:00AM  Alexion Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today CCBN
07:07AM  Q2 2014 Alexion Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
06:30AM  Alexion Reports Second Quarter 2014 Results Business Wire
06:17AM  Alexion's hypophosphatasia candidate MAA accepted by European Medicines Agency at theflyonthewall.com
06:15AM  European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Business Wire
23-Jul-14 06:17PM  Biogen, Gilead Earnings Crush Q2 Estimates Investor's Business Daily
04:40PM  Will Alexion Pharmaceuticals (ALXN) Miss This Earnings Season? Zacks
04:16PM  S&P 500 Posts New High; Biotechs, Airlines, Builders Up at Investor's Business Daily
01:29PM  S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade at Investor's Business Daily
01:16PM  Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 Zacks
11:56AM  Video: Biogen Trounces Q2 Estimates On Tecfidera at Investor's Business Daily
11:56AM  Video: Biogen Trounces Q2 Estimates As Tecfidera Outperforms at Investor's Business Daily
11:56AM  Biogen Trounces Q2 Estimates As Tecfidera Outperforms at Investor's Business Daily
10:15AM  Trade-Ideas: Alexion Pharmaceuticals (ALXN) Is Today's Unusual Social Activity Stock at TheStreet
22-Jul-14 12:42PM  Alexion, 3 Other Top Biotechs Reporting Earnings at Investor's Business Daily
10:04AM  Trade-Ideas: Alexion Pharmaceuticals (ALXN) Is Today's Momo Momentum Stock at TheStreet
08:32AM  Down 47%: Why the Market is Wrong About Celldex Stock at Motley Fool
21-Jul-14 10:40AM  Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More? at Seeking Alpha
19-Jul-14 08:02AM  Facebook, Gilead Headline IBD 50's Top 5 Earnings at Investor's Business Daily
18-Jul-14 06:47PM  Will New Drug Give Alexion Pharmaceuticals A Boost? at Investor's Business Daily
12:37PM  People Moves: Exiger, Och-Ziff, Pegasystems at The Wall Street Journal
09:15AM  Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings at 24/7 Wall St.
17-Jul-14 11:47AM  Gilead Sciences: Does Anyone Think It's Not Going to Beat? at Barrons.com
16-Jul-14 10:01AM  Pegasystems appoints Warner Chief Compliance Officer at theflyonthewall.com
09:31AM  Why Salix Pharmaceuticals Is Doing Right by Investors at Motley Fool
09:12AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
08:00AM  Alexion Announces the Appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to Its Board of Directors Business Wire
11-Jul-14 06:50PM  Inside The IBD 50: Leaders Show Mixed Action at Investor's Business Daily
10-Jul-14 10:07AM  22 stocks that may be the gems of earnings season at MarketWatch
10:00AM  Alexion Pharmaceuticals to Report Second Quarter 2014 Results on Thursday, July 24, 2014 Business Wire
09-Jul-14 12:49PM  22 stocks that may be the gems of earnings season at MarketWatch
08:57AM  22 stocks that may be the gems of earnings season at MarketWatch
08-Jul-14 04:10PM  Raptor Pharmaceuticals CEO to Retire, Appoints Successor Zacks
02:42PM  Alexion Pharma Looks To Life Beyond Its Blockbuster at Investor's Business Daily
07-Jul-14 04:01PM  Raptor Announces CEO Succession Plan; Dr. Christopher Starr to Retire as CEO at Year-end 2014, Julie Anne Smith Named President and CEO-Designate GlobeNewswire
03-Jul-14 12:26PM  Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector Benzinga
10:36AM  4 Biotech Stocks Worth A Look Ahead Of FDA Approvals Benzinga
01-Jul-14 02:47PM  Tuesday Sector Leaders: Healthcare, Technology & Communications at Forbes
30-Jun-14 02:06AM  Lifting the Curtain on Healthcare's Most Expensive Drugs at Motley Fool
27-Jun-14 02:40PM  Friday Sector Laggards: Materials, Healthcare at Forbes
02:40PM  Friday Sector Laggards: Materials, Healthcare
12:03PM  Stocks Mixed As Losses Pared; Foot Locker Steps Up at Investor's Business Daily
12:03PM  Stocks Mixed As Losses Pared; Foot Locker Steps Up
26-Jun-14 11:26AM  3 Stocks for Biotech's Hottest Trend at Motley Fool
11:26AM  3 Stocks for Biotech's Hottest Trend
25-Jun-14 01:04PM  VRTX, ICPT And ALXN, 3 Drugs Stocks Pushing The Industry Lower at TheStreet
01:04PM  VRTX, ICPT And ALXN, 3 Drugs Stocks Pushing The Industry Lower
24-Jun-14 05:05PM  [video] Upside ahead for Vertex: Pro at CNBC
05:05PM  [video] Upside ahead for Vertex: Pro
23-Jun-14 06:30AM  Alexion and Cincinnati Childrens Launch Rare Disease Innovation Fund Business Wire
06:30AM  Alexion and Cincinnati Childrens Launch Rare Disease Innovation Fund
20-Jun-14 06:35PM  Growth Stocks Kick Into Gear In Latest IBD 50 Screen at Investor's Business Daily
06:35PM  Growth Stocks Kick Into Gear In Latest IBD 50 Screen
03:00PM  Friday Sector Leaders: Energy, Healthcare at Forbes
19-Jun-14 04:50PM  Valeant Launches Hostile Bid for Allergan Zacks
04:50PM  Valeant Launches Hostile Bid for Allergan
01:07PM  3 Stocks Pushing The Health Care Sector Downward at TheStreet
01:07PM  3 Stocks Pushing The Health Care Sector Downward
18-Jun-14 10:30AM  Alexion's Soliris Gets Orphan Drug Status for New Indication Zacks
10:30AM  Alexion's Soliris Gets Orphan Drug Status for New Indication
09:33AM  Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar Zacks
09:33AM  Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar
17-Jun-14 04:20PM  J&J's Velcade in Focus at the European Hematology Association Zacks
04:00PM  Vertex Pharmaceuticals Crumbles on Analyst Worries Zacks
09:16AM  Tuesdays Top Biotech Stories: Alexion, Isis, and GW Pharmaceuticals at Motley Fool
09:16AM  Tuesdays Top Biotech Stories: Alexion, Isis, and GW Pharmaceuticals
06:40AM  Alexion granted ODD to Soliris by FDA at theflyonthewall.com
06:40AM  Alexion granted ODD to Soliris by FDA
06:39AM  FDA Grants Orphan Drug Designation to SolirisĀ® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) Business Wire
06:39AM  FDA Grants Orphan Drug Designation to SolirisĀ® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BELL LEONARDCEOAug 15Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 15Sale170.0635,0005,952,1001,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Sale165.9235,0005,807,3661,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 13Option Exercise17.6524,542433,1661,051,728Aug 13 07:10 PM
BELL LEONARDCEOAug 13Sale162.5224,5423,988,5941,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 12Option Exercise17.6580,4581,420,0841,107,644Aug 13 07:10 PM
BELL LEONARDCEOAug 12Sale160.1680,45812,885,9101,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 04Sale157.885,145812,2931,027,186Aug 05 04:55 PM
Hallal DavidEVP, Chief Commercial OfficerAug 04Sale158.001,349213,142118,616Aug 05 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerAug 04Sale157.421,662261,632106,944Aug 05 04:55 PM
Carmichael ClareSVP, Chief HR OfficerAug 04Sale158.2318429,11416,576Aug 05 04:54 PM
Sinha VikasEVP & CFOAug 04Sale157.821,525240,676162,770Aug 05 04:54 PM
BELL LEONARDCEOJul 30Option Exercise17.6520,489361,6311,052,820Jul 30 05:08 PM
BELL LEONARDCEOJul 30Sale165.6920,4893,394,8331,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 29Option Exercise17.651,20021,1801,033,531Jul 30 05:08 PM
BELL LEONARDCEOJul 29Sale164.931,200197,9161,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 28Option Exercise17.65105,6001,863,8401,137,931Jul 30 05:08 PM
BELL LEONARDCEOJul 28Sale162.38105,60017,146,8011,032,331Jul 30 05:08 PM
BELL LEONARDCEOJun 20Option Exercise11.9290,2801,076,1381,122,611Jun 23 06:26 PM
BELL LEONARDCEOJun 20Sale163.6090,28014,770,1871,032,331Jun 23 06:26 PM
MACKAY MARTINEVP & Global Head of R&DJun 12Option Exercise104.8625,0002,621,50049,426Jun 13 05:31 PM
MACKAY MARTINEVP & Global Head of R&DJun 12Sale166.4225,0004,160,56524,426Jun 13 05:31 PM
KELLER WILLIAM RDirectorJun 05Option Exercise96.353,425329,99915,701Jun 06 04:14 PM
KELLER WILLIAM RDirectorJun 05Sale170.003,425582,25012,276Jun 06 04:14 PM
Veneman Ann MDirectorJun 04Sale170.011,236210,1324,682Jun 06 04:14 PM
BELL LEONARDCEOMay 27Option Exercise11.9270,000834,4001,102,331May 29 05:10 PM
BELL LEONARDCEOMay 27Sale166.1670,00011,631,3491,032,331May 29 05:10 PM
BELL LEONARDCEOMay 20Option Exercise10.5270,000736,1441,102,331May 22 04:49 PM
BELL LEONARDCEOMay 20Sale155.9670,00010,917,5281,032,331May 22 04:49 PM
MACKAY MARTINEVP & Global Head of R&DMay 14Sale160.853,574574,87824,426May 15 05:11 PM
PARVEN ALVIN SDirectorMay 13Option Exercise16.8312,276206,60517,116May 15 05:11 PM
PARVEN ALVIN SDirectorMay 13Sale160.7812,2761,973,7354,840May 15 05:11 PM
BELL LEONARDCEOApr 29Option Exercise10.2966,210681,3011,098,541Apr 30 05:03 PM
BELL LEONARDCEOApr 29Sale156.2666,21010,346,2561,032,331Apr 30 05:03 PM
BELL LEONARDCEOApr 28Option Exercise10.293,79038,9991,036,121Apr 30 05:03 PM
BELL LEONARDCEOApr 28Sale155.123,790587,9051,032,331Apr 30 05:03 PM
MADRI JOSEPH ADirectorMar 11Option Exercise9.5160,000570,600239,217Mar 13 05:03 PM
MADRI JOSEPH ADirectorMar 11Sale178.6160,00010,716,300179,217Mar 13 05:03 PM
Carmichael ClareSVP, Chief HR OfficerMar 03Sale174.7730553,30516,760Mar 04 05:35 PM
PARVEN ALVIN SDirectorFeb 11Sale174.062,471430,1024,840Feb 13 05:00 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 10Sale167.311,635273,552101,308Feb 10 06:47 PM
MADRI JOSEPH ADirectorFeb 07Option Exercise4.9330,000147,900209,217Feb 10 06:46 PM
Sinha VikasEVP & CFOFeb 07Sale155.571,620252,029137,900Feb 10 06:46 PM
Moriarty John BSVP & General CounselFeb 07Sale155.601,036161,19822,232Feb 10 06:46 PM
MADRI JOSEPH ADirectorFeb 07Sale159.0030,0004,770,000179,217Feb 10 06:46 PM
Wright Frank JSVP, President Alxn Pharm IntlFeb 07Sale155.571,098170,81919,670Feb 10 06:48 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 07Sale155.571,620252,030102,943Feb 10 06:47 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 07Sale155.571,610250,461113,965Feb 10 06:47 PM
BELL LEONARDCEOFeb 07Sale155.564,620718,672986,696Feb 10 06:48 PM
Carmichael ClareSVP, Chief HR OfficerFeb 07Sale155.561,006156,49613,765Feb 10 06:48 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 06Option Exercise93.833,800356,55498,618Feb 10 06:47 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 06Sale155.113,800589,41894,818Feb 10 06:47 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 06Sale156.95101,570113,965Feb 10 06:47 PM
BELL LEONARDCEOFeb 04Sale153.638,8701,362,698963,276Feb 05 07:56 PM
Carmichael ClareSVP, Chief HR OfficerFeb 04Sale153.63760116,7598,703Feb 05 07:56 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 04Sale153.632,390367,176105,830Feb 05 07:56 PM
Sinha VikasEVP & CFOFeb 04Sale153.632,700414,801129,775Feb 05 07:57 PM
MATHIS LARRYDirectorFeb 03Option Exercise23.5580,7291,901,540110,185Feb 05 07:57 PM
LINK MAXDirectorFeb 03Sale155.1640,0006,206,21958,574Feb 05 07:57 PM
Sinha VikasEVP & CFOFeb 03Sale157.14852133,883132,475Feb 05 07:57 PM
MATHIS LARRYDirectorFeb 03Sale157.5080,72912,714,58629,456Feb 05 07:57 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 03Sale157.14729114,555108,220Feb 05 07:56 PM
BELL LEONARDCEOFeb 03Sale157.142,920458,849972,146Feb 05 07:56 PM
BELL LEONARDCEOJan 29Sale133.812,660355,929975,066Jan 31 05:29 PM
Sinha VikasEVP & CFOJan 29Sale133.43994132,633133,327Jan 31 05:29 PM
Hallal DavidEVP, Chief Commercial OfficerJan 29Sale133.4572997,283108,949Jan 31 05:29 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerJan 29Sale133.311,118149,039103,068Jan 31 05:30 PM
BELL LEONARDCEOJan 22Option Exercise10.2912,817131,887990,543Jan 22 05:52 PM
BELL LEONARDCEOJan 22Sale141.4112,8171,812,397977,726Jan 22 05:52 PM
BELL LEONARDCEOJan 21Option Exercise8.19110,930908,0651,137,409Jan 22 05:52 PM
BELL LEONARDCEOJan 21Sale140.91110,93015,631,693977,726Jan 22 05:52 PM
BELL LEONARDCEOJan 17Option Exercise6.9032,689225,5541,076,351Jan 22 05:52 PM
BELL LEONARDCEOJan 17Sale140.2032,6894,582,8661,043,662Jan 22 05:52 PM
BELL LEONARDCEOJan 13Option Exercise6.9015,845109,3311,059,507Jan 15 06:19 PM
BELL LEONARDCEOJan 13Sale135.2515,8452,143,0361,043,662Jan 15 06:19 PM
BELL LEONARDCEOJan 10Option Exercise6.9011,70580,7651,043,662Jan 10 05:26 PM
BELL LEONARDCEOJan 10Sale135.0011,7051,580,1751,031,957Jan 10 05:26 PM
BELL LEONARDCEOJan 09Option Exercise6.901,0397,1691,032,996Jan 10 05:26 PM
BELL LEONARDCEOJan 09Sale135.051,039140,3171,031,957Jan 10 05:26 PM
BELL LEONARDCEOJan 08Option Exercise5.426,41134,7761,038,368Jan 10 05:26 PM
BELL LEONARDCEOJan 08Sale134.936,411865,0361,031,957Jan 10 05:26 PM
BELL LEONARDCEODec 19Option Exercise5.1835,000181,3001,066,957Dec 20 04:24 PM
BELL LEONARDCEODec 19Sale129.9035,0004,546,5001,031,957Dec 20 04:24 PM
Hallal DavidEVP, Chief Commercial OfficerDec 18Option Exercise17.987,295131,164116,973Dec 20 04:25 PM
Sinha VikasEVP & CFODec 18Option Exercise17.6532,026565,259166,347Dec 20 04:24 PM
BELL LEONARDCEODec 18Option Exercise5.62145,664818,5701,171,957Dec 20 04:24 PM
BELL LEONARDCEODec 18Sale125.49140,00017,569,1491,031,957Dec 20 04:24 PM
Sinha VikasEVP & CFODec 18Sale127.8132,0264,093,243134,321Dec 20 04:24 PM
Hallal DavidEVP, Chief Commercial OfficerDec 18Sale127.6115,3631,960,472109,678Dec 20 04:25 PM
Hallal DavidEVP, Chief Commercial OfficerDec 18Sale127.537,295930,331109,678Dec 20 04:25 PM
Hallal DavidEVP, Chief Commercial OfficerDec 09Option Exercise17.9814,637263,173124,315Dec 11 08:56 PM
Hallal DavidEVP, Chief Commercial OfficerDec 09Option Exercise17.9810,705192,476120,383Dec 11 08:56 PM
Sinha VikasEVP & CFODec 09Option Exercise17.6517,974317,241152,295Dec 11 08:56 PM
Hallal DavidEVP, Chief Commercial OfficerDec 09Sale127.6314,6371,868,120109,678Dec 11 08:56 PM
Hallal DavidEVP, Chief Commercial OfficerDec 09Sale127.6310,7051,366,279109,678Dec 11 08:56 PM
Sinha VikasEVP & CFODec 09Sale127.6617,9742,294,561134,321Dec 11 08:56 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerNov 04Option Exercise31.6414,125446,963118,311Nov 05 06:50 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerNov 04Sale123.8714,1251,749,664104,186Nov 05 06:50 PM
Sinha VikasEVP & CFOOct 28Option Exercise17.6550,000882,500360,808Oct 30 06:00 PM